Negotiations between Algeria and Russia to locally produce the Covid Sputnik V vaccine are progressing. The Algerian government has taken another step towards making this project a reality, which will allow our country to produce one of the most effective anti-Covid vaccines in the world, in order to immunize its own population, and to supply neighboring and African countries.
On Friday, the director general of the National Pharmaceuticals Agency (ANPP), Prof. Kamel Mansouri, reported on discussions between the public pharmaceutical group Saidal and a Russian operator for the production in Algeria of Sputnik V. Since then, negotiations between Russia and Algeria have advanced.
The Algerian government has designated the Saidal group as the “exclusive partner” of the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, which financed the design of Sputnik V by the Russian National Center for Epidemiology and Microbiology Gamaleya.
“The Algerian government has decided to designate the Saidal group as the exclusive partner of the Russian Direct Investment Fund,” Pharmaceutical Industry Minister Lotfi Benbahmed told TSA on Thursday.
Algeria began the Covid-19 vaccination campaign on January 30, after receiving 50,000 doses of the Russian Sputnik vaccine the day before, out of a total order of 500,000 units.
On December 30, 2020, the government announced that it had chosen the Russian vaccine Sputnik V to begin its vaccination campaign against Covid-19.
Yesterday Wednesday, the media Russia Beyond, quoting Ivan Nalitch, sales representative of Russia in Algeria, reported discussions with the private Algerian laboratory Frater-Razes for the production of Sputnik V in Algeria.
